Byetta FDA Approval History
FDA Approved: Yes (First approved April 28, 2005)
Brand name: Byetta
Generic name: exenatide
Dosage form: Injection
Company: Amylin Pharmaceuticals / Eli Lilly & Co.
Treatment for: Diabetes, Type 2
Byetta (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Development Timeline for Byetta
|Oct 20, 2011||ApprovalByetta Approved for Use with Insulin Glargine in the U.S.|
|Nov 2, 2009||ApprovalByetta Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes|
|Apr 28, 2005||ApprovalByetta Amylin Pharmaceuticals / Eli Lilly & Co. - Treatment for Type 2 Diabetes|
|Sep 1, 2004||Exenatide New Drug Application Accepted for Review by the FDA|
|Jun 30, 2004||New Drug Application for Exenatide Submitted to FDA for Type 2 Diabetes|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.